International Journal of Clinical Research

Objective To explore the clinical efficacy and feasibility of budesonide nebulization combined with ambroxol in the early treatment of patients with pulmonary contusion. Methods Ninety patients diagnosed with pulmonary contusion admitted to our hospital from July 2023 to December 2024 were randomly divided into an observation group and a control group, with 45 cases in each group, according to the admission order. The control group received routine basic treatments such as anti infection, hemostasis, and oxygen therapy, while the observation group received a combination of intravenous ambroxol injections (30mg, twice a day) or oral ambroxol tablets (60mg, three times a day) on this basis. Compare the cough relief time, changes in dyspnea score, disappearance rate of lung rales, improvement of chest CT, and length of hospital stay between two groups of patients on the 7th day after treatment. Results The cough relief time in the observation group was significantly shorter than that in the control group (P<0.05), and the improvement in dyspnea score on the 7th day was more significant (P<0.05). The disappearance rate of lung rales and the improvement rate of chest CT were higher than those in the control group (P<0.05). The average length of hospital stay was shortened by 2.3 days, and the difference was statistically significant. Conclusion The combination of budesonide nebulization and intravenous application of ambroxol can significantly improve early respiratory symptoms, promote lung recovery, shorten hospitalization time in patients with pulmonary contusion, and is suitable for promotion and use in hospitals.

Pulmonary contusion; Budesonide; Ambroxol; Nebulized inhalation; Combined therapy; Respiratory management